|
Greenworx Holding
|
Oplombeekstraat 6
1755 Gooik
|
 |
Saffelberg Investments holds 50% of the shares of Greenworx Holding N.V. in a partnership with entrepreneurs Serge Ameye and Tom Hanson. Greenworx actively seizes opportunities in the field of renewable energy and environmental projects, primarily targeting Eastern and South Eastern Europe.
Greenworx has currently co-developed a large scale rendering plant in Serbia, ZELENA, as a joint venture with Belgian market leader ElectraWinds and local Serbian partners.
Greenworx Holdings recently also acquired a development company with a potential development of a 250 mWatt windmill farm in the Ukraine. This project is realized in a 50/50 partnership with Güris, one of the main players in renewable energy in Turkey.
Belspeed
|
Industrie Zone 6 C
9770 Kruishoutem
T: +32 9 338 54 54
|
Rue de l'Eurégio 5
4700 Eupen
T: +32 87 59 87 70
|
http://www.belspeed.eu
|
As a logistics partner, BELSPEED has been providing an exquisite service to the fashion elite for the past 25 years. It stands for secure and punctual delivery of millions of clothing items, by sea or air traffic, from factories worldwide to distributors throughout Western and Eastern Europe and new emerging markets. On hangers and in boxes, sorted and packed, or as bulk, the shipments are processed and delivered with streamlined precision, personal attention, integrity and efficiency.
Uteron Pharma Holding
|
Rue du Travail 16
4460 Grâce-Hollogne
|
 |
Uteron Pharma Holding (Uteron), based in Liege (Belgium), was founded in 2006 as a collaboration between the University of Liege, the Walloon Region, and Mithra pharmaceuticals. Based on its innovative controlled release technology platform, which allows a prolonged release of active pharmaceutical ingredients, Uteron has developed a hormonal intra‐uterine device (IUD). An IUD is a flexible T‐shaped frame that once inserted in the uterus provides an effective, safe, reversible and long term protection against pregnancy. About 150 million women worldwide rely on an IUD. In contrast to most other IUD's available the Uteron IUD consistently releases a constant low dose of a synthetic hormone. Extensive clinical trials to prove contraception are currently being conducted in cooperation with its US based development partner Medicines360.
CDM
|
Reutenbeek 9-11
B - 3090 Overijse
T: +32 2 687 79 07
|
|
CDM [Customized Design of Mass-spring-systems] is a company with a passion for comfort. They are in business since 1951, specialising in the design, production and implementation of noise and vibration isolation systems.
Their dedicated team of engineers and technical designers is active worldwide in the segments building, industry and railway infrastructure (track). This team searches for the best possible solutions for your specific noise or vibration problem.
Gemaco
|
Carlistraat 11
1140 Brussel
T: +32 2 240 03 70
|
|
For 30 years Gemaco has been the market leader in promotional items and advertising gifts. Gemaco has a fully integrated business model from sourcing and production in the Far East until just in time delivery. Gemaco supports global customers in their promotion strategy.
Altachem
Altachem nv, established in 1992 and located in Deinze (Belgium) is the world leader in the development and production of:
- Specialty aerosol valves for One Component polyurethane Foam (OCF);
- NBS foam applicators (foam guns) and systems;
- Specialty chemicals used in OCF formulations.
Mercator Press
Mercator Press Group is a commercial printer, established more than 40 years ago. The Group is the market leader in rotary printing.
Mercator Press Group has 3 plants with the latest rotary presses and extensive machinery comprising 16-, 24-, 32- and 48-page presses. In addition to the continuous training of the over 250 trained staff and the very latest machinery, they never leave anything to chance. Constant attention is focused on ISO-standards and environmentally friendly production.
Pharmaneuroboost
PharmaNeuroBoost (PNB) - founded in 2006 - is a young biopharmaceutical company dedicated to developing best in class CNS therapeutics. The company's primary goal is to exploit the PNB01 and PNB02 opportunity. Both innovative designed drugs are a combination medicine that strives to reinforce the effect of SSRIs, an important class of anti-depressants (PNB01) and of atypical antipsychotics (PNB02).
In 2008, Saffelberg Investments has invested 2.5 million EUR in exchange for a stake of 16% in PNB. Other shareholders are KBC Private Equity, KBC ARKIV, Rudi Mariën and management.
|
